Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RVTY Stock Forecast 2025-2026
$91.25
Current Price
$10.76B
Market Cap
Buy 14
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to RVTY Price Targets
+77.5%
To High Target of $162.00
+31.5%
To Median Target of $120.00
+9.6%
To Low Target of $100.00
RVTY Price Momentum
-1.7%
1 Week Change
-3.8%
1 Month Change
-12.9%
1 Year Change
-18.2%
Year-to-Date Change
-29.5%
From 52W High of $129.50
+3.1%
From 52W Low of $88.53
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Revvity Inc (RVTY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RVTY and similar high-potential opportunities.
Latest RVTY Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, RVTY has a bullish consensus with a median price target of $120.00 (ranging from $100.00 to $162.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $91.25, the median forecast implies a 31.5% upside. This outlook is supported by 14 Buy, 6 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Rachel Vatnsdal at JP Morgan, suggesting a 9.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RVTY Analyst Ratings
14
Buy
6
Hold
0
Sell
RVTY Price Target Range
Low
$100.00
Average
$120.00
High
$162.00
Current: $91.25
Latest RVTY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RVTY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 1, 2025 | UBS | Dan Leonard | Buy | Upgrade | $115.00 |
| Apr 29, 2025 | JP Morgan | Rachel Vatnsdal | Neutral | Maintains | $100.00 |
| Apr 29, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $125.00 |
| Apr 29, 2025 | Baird | Catherine Ramsey | Outperform | Maintains | $125.00 |
| Apr 29, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $120.00 |
| Apr 21, 2025 | Baird | Catherine Ramsey | Outperform | Maintains | $127.00 |
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $102.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $110.00 |
| Feb 3, 2025 | Keybanc | Paul Knight | Overweight | Maintains | $145.00 |
| Feb 3, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $145.00 |
| Feb 3, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $140.00 |
| Jan 21, 2025 | Raymond James | Andrew Cooper | Outperform | Maintains | $140.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Upgrade | $138.00 |
| Nov 25, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $135.00 |
| Nov 5, 2024 | Raymond James | Andrew Cooper | Outperform | Maintains | $146.00 |
| Nov 5, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $138.00 |
| Nov 5, 2024 | Bernstein | Eve Burstein | Outperform | Maintains | $145.00 |
| Nov 5, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $144.00 |
| Oct 17, 2024 | Leerink Partners | Outperform | Maintains | $135.00 | |
| Oct 15, 2024 | Barclays | Luke Sergott | Overweight | Upgrade | $140.00 |
Revvity Inc. (RVTY) Competitors
The following stocks are similar to Revvity Inc based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Revvity Inc. (RVTY) Financial Data
Revvity Inc. has a market capitalization of $10.76B with a P/E ratio of 37.7x. The company generates $2.77B in trailing twelve-month revenue with a 10.3% profit margin.
Revenue growth is +2.3% quarter-over-quarter, while maintaining an operating margin of +12.2% and return on equity of +3.8%.
Valuation Metrics
Market Cap
$10.76B
Enterprise Value
$12.94B
P/E Ratio
37.7x
PEG Ratio
17.7x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
+2.3%
Gross Margin
+56.5%
Operating Margin
+12.2%
Net Margin
+10.3%
EPS Growth
+62.4%
Financial Health
Cash/Price Ratio
+10.6%
Current Ratio
3.6x
Debt/Equity
43.5x
ROE
+3.8%
ROA
+2.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Revvity Inc. (RVTY) Business Model
About Revvity Inc.
What They Do
Provides innovative solutions for healthcare and life sciences.
Business Model
Revvity Inc. generates revenue by offering a range of products and services, including diagnostic tools and analytical capabilities tailored for the biotechnology, pharmaceutical, and clinical diagnostics sectors. The company leverages its expertise in advanced technologies to provide essential solutions that support disease discovery, drug development, and health monitoring, thereby enhancing global health outcomes.
Additional Information
Revvity's commitment to improving healthcare delivery is reflected in its focus on personalized medicine and preventive healthcare, positioning it as a key player in advancing medical and scientific research. The company's global presence allows it to serve a diverse clientele and contribute significantly to the scientific community.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
11,000
CEO
Dr. Prahlad R. Singh Ph.D.
Country
United States
IPO Year
1983
Website
www.revvity.comRevvity Inc. (RVTY) Latest News & Analysis
Latest News
Quick Summary
Revvity reports Q1 results exceeding expectations and maintains full-year guidance despite challenges like declining biotech funding and regulatory uncertainty.
Why It Matters
Revvity's strong Q1 results despite sector challenges indicate resilience, but ongoing funding and regulatory issues could impact future growth, affecting stock performance potential.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Revvity, Inc. (NYSE: RVTY) will present at the Bank of America Global Healthcare Conference on May 13, 2025, and the Goldman Sachs Healthcare Conference on June 10, 2025.
Why It Matters
Revvity's participation in major investor conferences signals potential growth insights and strategic updates, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Revvity's Q1 results exceeded Wall Street expectations, and the company upheld its full-year profit forecast, driven by strong demand from biotech clients for medical research equipment.
Why It Matters
Revvity's strong Q1 results and maintained profit forecast indicate robust demand from biotech, signaling potential growth and stability, which can positively influence investor sentiment and stock performance.
Source: Reuters
Market Sentiment:
Positive
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
14 days ago
Quick Summary
Revvity Inc. (RVTY) stock rose on Monday following the release of better-than-expected earnings for Q1 2025.
Why It Matters
Revvity Inc.'s higher stock price reflects strong earnings performance, indicating potential growth and profitability, which can attract more investors and drive future stock value.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Revvity, Inc. (NYSE:RVTY) will hold its Q1 2025 Earnings Conference Call on April 28, 2025, at 8:00 AM ET, featuring key executives and analysts from major firms.
Why It Matters
The upcoming Q1 2025 earnings call for Revvity, Inc. will provide key financial insights and performance metrics, influencing market sentiment and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Revvity, Inc. (NYSE: RVTY) reported Q1 2025 earnings with EPS of $0.35, up from $0.21 YoY. Revenue increased to $665 million from $650 million, and operating income rose to $72 million from $44 million.
Why It Matters
Revvity's Q1 earnings show significant growth in EPS and operating income, indicating strong financial health and potential for continued investment return. Revenue increase also signals market demand.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RVTY Stock
What is Revvity Inc.'s (RVTY) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, Revvity Inc. (RVTY) has a median price target of $120.00. The highest price target is $162.00 and the lowest is $100.00.
Is RVTY stock a good investment in 2025?
According to current analyst ratings, RVTY has 14 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $91.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RVTY stock?
Wall Street analysts predict RVTY stock could reach $120.00 in the next 12 months. This represents a 31.5% increase from the current price of $91.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Revvity Inc.'s business model?
Revvity Inc. generates revenue by offering a range of products and services, including diagnostic tools and analytical capabilities tailored for the biotechnology, pharmaceutical, and clinical diagnostics sectors. The company leverages its expertise in advanced technologies to provide essential solutions that support disease discovery, drug development, and health monitoring, thereby enhancing global health outcomes.
What is the highest forecasted price for RVTY Revvity Inc.?
The highest price target for RVTY is $162.00 from at , which represents a 77.5% increase from the current price of $91.25.
What is the lowest forecasted price for RVTY Revvity Inc.?
The lowest price target for RVTY is $100.00 from Rachel Vatnsdal at JP Morgan, which represents a 9.6% increase from the current price of $91.25.
What is the overall RVTY consensus from analysts for Revvity Inc.?
The overall analyst consensus for RVTY is bullish. Out of 23 Wall Street analysts, 14 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $120.00.
How accurate are RVTY stock price projections?
Stock price projections, including those for Revvity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 12:29 PM UTC